EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ferroptosis as an emerging therapeutic target in liver diseases

Yuzhen Lu, Junjie Hu, Liang Chen, Shan Li, Ming Yuan, Xianxiang Tian, Peng Cao, Zhenpeng Qiu

Frontiers in Pharmacology · 15.05.2023 · 14

DOI: 10.3389/fphar.2023.1196287 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.05.2023. Verfasst von Yuzhen Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis is an iron-dependently nonapoptotic cell death characterized by excessive accumulation of lipid peroxides and cellular iron metabolism disturbances. Impaired iron homeostasis and dysregulation of metabolic pathways are contributors to ferroptosis. As a major metabolic hub, the liver synthesizes and transports plasma proteins and endogenous fatty acids. Also, it acts as the primary location of iron storage for hepcidin generation and secretion. To date, although the intricate correlation between ferroptosis and liver disorders needs to be better defined, there is no doubt that ferroptosis participates in the pathogenesis of liver diseases. Accordingly, pharmacological induction and inhibition of ferroptosis show significant potential for the treatment of hepatic disorders involved in lipid peroxidation. In this review, we outline the prominent features, molecular mechanisms, and modulatory networks of ferroptosis and its physiopathologic functions in the progression of liver diseases. Further, this review summarizes the underlying mechanisms by which ferroptosis inducers and inhibitors ameliorate liver diseases. It is noteworthy that natural active ingredients show efficacy in preclinical liver disease models by regulating ferroptosis. Finally, we analyze crucial concepts and urgent issues concerning ferroptosis as a novel therapeutic target in the diagnosis and therapy of liver diseases.

Schlagwörter

Stichwörter der Autor:innen

acute liver failureferroptosishepatitishepatocellular carcinomaliver fibrosisnonalcoholic fatty liver disease

Autor:innen und Institutionen

  • College of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
  • Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China.
  • Department of Biochemistry, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lu, Y., Hu, J., Chen, L., Li, S., Yuan, M., Tian, X., Cao, P., & Qiu, Z. (2023). Ferroptosis as an emerging therapeutic target in liver diseases. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1196287

Vancouver

Lu Y, Hu J, Chen L, Li S, Yuan M, Tian X, et al. Ferroptosis as an emerging therapeutic target in liver diseases. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1196287

BibTeX
@article{Lu2023,
  author = {Lu, Yuzhen and Hu, Junjie and Chen, Liang and Li, Shan and Yuan, Ming and Tian, Xianxiang and Cao, Peng and Qiu, Zhenpeng},
  title = {Ferroptosis as an emerging therapeutic target in liver diseases},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1196287}
}
Kostenlos starten →